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Abstract
CHARGE syndrome is a variable, multiple congenital malformation syndrome. Patients
with CHARGE syndrome have frequent infections that are presumed to be due to anatomi-
cal anomalies of the craniofacial region and upper airway, and cranial nerve problems
resulting in swallowing difficulties and aspiration. The possible contribution of immunologi-
cal abnormalities to these infections has not been systematically studied even though
immune deficiencies have been described in patients with 22q11.2 deletion syndrome, a
condition which shares remarkable clinical overlap with CHARGE syndrome. We
assessed the frequency and nature of immune dysfunction in 24 children with genetically
proven CHARGE syndrome. All patients, or their parents, completed a questionnaire on
infectious history. Their immune system was extensively assessed through full blood
counts, immunoglobulin levels, lymphocyte subpopulations, peripheral B- and T-cell dif-
ferentiation, T-receptor excision circle (TREC) analysis, T-cell function, and vaccination
responses. All CHARGE patients had a history of infections (often frequent), mainly otitis
media and pneumonia, leading to frequent use of antibiotics and to hospital admissions.
Decreased T-cell numbers were found in 12 (50%) patients, presumably caused by insuffi-
cient thymic output since TREC amounts were also diminished in CHARGE patients.
Despite normal peripheral B-cell differentiation and immunoglobulin production in all
patients, 83% of patients had insufficient antibody titers to one or more early childhood
vaccinations. Based on our results, we recommend immunological evaluation of CHARGE
patients with recurrent infections.
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Introduction
CHARGE syndrome (MIM# 214800) is a rare, multiple congenital anomaly syndrome with an
estimated birth prevalence of 1 in 15,000 to 17,000 newborns [1]. The clinical diagnosis is
made using criteria proposed by Blake et al. [2] or Verloes [3]. The syndrome is caused by a
dominant loss-of-function mutation in, or a deletion of, the CHD7 gene (#MIM 608892),
which usually occurs de novo and can be found in over 90% of all children who meet the clini-
cal diagnostic criteria. The encoding protein of CHD7 is a member of the chromodomain heli-
case DNA-binding protein family that regulates the transcription of genes during embryonic
development. Because of the regulating function of CHD7, haploinsufficiency of CHD7 affects
multiple organ systems, which explains the broad clinical variability seen in CHARGE syn-
drome. No clear genotype-phenotype correlations have been found, although variants leading
to a premature stop codon are, in general, associated with a more severe phenotype than vari-
ants with a non-truncating effect (i.e. missense variants) [4].
Since Pagon et al. [5] proposed the acronym CHARGE (Coloboma of the eye, Heart defects,
Atresia of the choanae, Retardation of growth and/or development, Genital abnormalities, and
Ear abnormalities), new clinical features have been added to CHARGE syndrome that include
cranial nerve dysfunction, absent or hypoplastic semicircular canals, anosmia, cleft lip and/or
palate, and skeletal abnormalities [3,6,7]. In addition, patients with CHARGE syndrome have
frequent infections including recurrent otitis media, sinusitis, and infections of the respiratory
tract, which lead to morbidity and even mortality [8,9]. Deviations of the palatal and ear anat-
omy, as well as cranial nerve dysfunction affecting swallowing, contribute to these infections.
However, the contribution of abnormalities in the immune system may be of importance
because T-cell lymphopenia and thymic abnormalities have been described in individual
patients with CHARGE syndrome, and these abnormalities resemble immune abnormalities
seen in 22q11.2 deletion syndrome (#MIM 192430) [9]. In contrast to 22q11.2 deletion syn-
drome, the frequency and exact nature of the immunological abnormalities in CHARGE syn-
drome have so far not been studied either prospectively or systematically. In this respect,
knowledge is needed to develop guidelines to optimize the care of children with CHARGE syn-
drome. Our aim in this study was to systematically explore the prevalence and nature of
immune dysfunction in children with CHARGE syndrome.
Patients and Methods
Patients
Children with genetically confirmed CHARGE syndrome were recruited through the Dutch
Expert Clinic for CHARGE syndrome between September 2013 and June 2014. Mutations in
CHD7 were classified as truncating (i.e. nonsense, frameshift, or deletion) or non-truncating (i.
e. missense or splice-site). Healthy children, mainly siblings of CHARGE patients, were
included as age-matched controls for the T-cell function assay and as a control group for the
T-cell receptor excision circle (TREC) analysis. Exclusion criteria were age below 20 months or
above 18 years or active infection and/or immunosuppressive therapy (e.g. steroids) at the time
of the blood tests. Further exclusion criteria for healthy controls were ear-nose-throat problems
in the previous two years defined as adenoidectomy, placement of tympanostomy tubes, or oti-
tis media with effusion. Potential healthy controls with primary immune deficiencies or auto-
immune disease were also excluded.
Patients, or their parents, filled in a Dutch questionnaire on infectious history (available
from the authors upon request). Questions were based on international guidelines and proto-
cols for identifying primary immune deficiency [10,11]. Additional medical information was
Immune Dysfunction in CHARGE Syndrome
PLOSONE | DOI:10.1371/journal.pone.0142350 November 6, 2015 2 / 16
extracted from the patient files and the database of the Dutch Expertise Centre for CHARGE
syndrome. Because the thymus has not been routinely examined in CHARGE patients, infor-
mation on the thymus could only be retracted from cardiac surgery reports, where available.
The study was approved by the Medical Ethical Review Committee of the University Medical
Centre Groningen and written informed consent was obtained from all patients, controls and/
or their parents.
Immunologic assays
Peripheral blood was obtained from all patients and healthy controls for immunological assess-
ment. All the immunological assays we performed have been validated and are used in routine
patient diagnostics. For all assays, age-matched reference values are available [12–15], except
for the T-cell subpopulations of patients under the age of 5 years, TRECs, and T-cell function
assay [16]. Healthy controls were used to establish age-matched reference values for the T-cell
function assay and as the control group for TREC analysis. Lymphocyte populations and
peripheral B- and T-cell subpopulations were also analysed in the healthy controls. Results of
all assays, except for the TRECs, were assessed on the basis of the age-matched reference
values.
Full blood counts were measured with an automated cell counter (Sysmex XN10/20, Kobe,
Japan); serum immunoglobulin (Ig) G, IgG subclasses 1–4, IgA, and IgM were nephelometri-
cally analysed using BNII system (Siemens AG, Munich, Germany); and serum total IgE was
measured by fluoro-enzyme-immuno-assay (Phadia, Uppsala, Sweden). These assays were per-
formed according to the manufacturer’s protocol.
IgG-specific antibodies to diphtheria toxoid and tetanus toxin were analysed at the National
Institute for Public Health and the Environment (RIVM, Netherlands) using a Luminex-tech-
nology-based multiplex immunoassay developed in-house [17,18]. A protective concentration
of antibody to both diphtheria and tetanus was defined as0.10 IU/ml. IgG-specific antibodies
toHaemophilus influenzae type b and to 13 types of pneumococcal polysaccharides were ana-
lysed at the laboratory of the Antonius Hospital (Nieuwegein, Netherlands). Enzyme-linked
immunosorbent assay (ELISA, Binding Site, San Diego, CA, USA) was used to analyse IgG-spe-
cific antibodies toH. influenzae type b and a concentration of>1.0 mg/l was considered pro-
tective. IgG-specific antibodies to pneumococcal polysaccharides were analysed by multiplex
assay [19,20]. An adequate response to pneumococcal polysaccharides was defined as an abso-
lute level of>0.35 μg/ml in> 50% of the serotypes.
Multicolour flow cytometric phenotyping of the lymphocyte populations was performed
using a FACSCanto II (Becton Dickinson, Franklin Lakes, NJ, USA) and data were analysed
using FACSCanto Clinical Software version 2.4 and FACSDiva software version 7.0 (Becton
Dickinson). Absolute numbers of CD3+, CD4+, and CD8+ T-cells; CD19+ B-cells; and CD16
+/56+ NK-cells were measured using the MultiTest TruCount method with MultiTest reagents
to CD45/3/4/8/16+56/19 (Becton Dickinson). The lyse-no-wash preparation method was per-
formed as prescribed by the manufacturer.
Peripheral B- and T-cell differentiation was assessed by multicolour flow cytometric pheno-
typing of the peripheral B- and T-cell subpopulations based on the methods described by
Driessen et al. [14]. The monoclonal antibodies and the gating strategy for the B- and T-cell
subpopulations are discussed in S1 Appendix. Absolute numbers of the B- and T-cell subpopu-
lations were calculated using their relative numbers and the absolute number of CD19+ B-cells
or CD4+ and CD8+ T-cells. Absolute numbers of the B- and T-cell subpopulations were then
compared to age-matched reference values [14,15]. Because of the heterogeneity of the
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peripheral T-cells, T-cell subpopulations were only considered to be decreased if both the abso-
lute and relative numbers were lower than the age-matched reference values.
TRECs, which can be used as a reflection of thymic T-cell output [21], were assessed by the
methods proposed by Hazenberg et al. [22] and Chan and Puck [23]. In brief, DNA was
extracted from dry blood spots using generation DNA elution solution method (Qiagen, Hil-
den, Germany). Subsequently, real-time quantitative PCR for TRECs was performed with
Albumin as control for DNA input. The amount of TRECs per μg DNA was calculated.
T-cell function was assessed by stimulating whole blood with five different stimuli and mea-
suring T-cell activation (percentage CD69+ T-cells) and cytokine production (TNF-α, IFN-γ,
IL-2, IL-4) as described by us earlier [16] and further described in S2 Appendix. T-cell activa-
tion and intracellular production of cytokines were determined within the CD4+ and CD8+ T-
cells. The interpretation of these T-cell function tests was done by the medical immunologist
(AJAL) who has extensive experience with it in our immunologic laboratory.
Statistical analysis
We used descriptive statistics to provide summary results on individual outcomes. Fisher’s
exact test was used to compare two groups of dichotomous outcomes. Student’s t test was used
to compare the TRECs results of the patients with the healthy control group. In addition, the
effect of age on the TRECs results was analysed with linear regression. A two-sided p-value
smaller than 0.05 was considered as significant. The statistical software programme IBM SPSS
Statistics for Windows, Version 22.0 (Armonk, NY: IBM Corp.) was used for statistical analy-
sis. To construct graphs, GraphPad Prism for Windows, Version 5.04 (La Jolla, CA, USA) was
used.
Results
Clinical characteristics
We initially included 27 patients and 14 healthy controls in the study. Two of the patients were
later excluded because blood sampling was unsuccessful, and one patient and two healthy con-
trols withdrew from the study. The clinical characteristics of the remaining 24 patients are pre-
sented in Table 1. The median ages of patients and controls were 8.3 (range 1.9–16.9) and 11.5
(range 5.5–17.3) years, respectively. Two-thirds of the mutations in CHD7 in our cohort are
known to lead to a premature stop in CHD7 (truncating mutations). All but five patients ful-
filled the clinical criteria for typical CHARGE syndrome as defined by Blake et al. [2] and/or
Verloes [3].
All 24 patients had a history of infections (often frequent). Twenty (83%) patients had expe-
rienced upper airway infections, including otitis media in 16 (67%) patients. Seven (29%)
patients had had pneumonia and eight (33%) patients had a history of other infections, includ-
ing dermatomucosal infections (n = 5), gastroenteritis (n = 1), and pyelonephritis (n = 2). Ten
(42%) patients had needed hospital admission for their infections, predominantly for pneumo-
nia (n = 5). In addition, 12 (50%) patients needed placement of tympanostomy tubes because
of recurrent otitis media. Antibiotics had been ever given to 17 (71%) patients and seven (29%)
patients had received prophylactic antibiotics for recurrent upper airway infections or pneu-
monia. None of the patients had had life-threatening infections like sepsis or meningitis. Can-
didiasis was only seen with concomitant antibiotic use. Atopic disorders (n = 8, 33%) were
mentioned as allergy (n = 6, 25%), eczema (n = 2, 8%) and asthma (n = 1, 4%). None of the
patients had an autoimmune disease.
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In summary, all CHARGE patients had a history of infections. Otitis media and pneumonia
were the most prevalent, with prophylactic antibiotics given to 29% of patients. Eighteen
patients (75%) needed hospital admission for reasons related to infectious diseases.
Full blood count
Haemoglobin levels, numbers of erythrocytes, thrombocytes, and leukocytes (including neu-
trophils, lymphocytes, basophils, eosinophils, and monocytes) were normal in all 24 patients.
Table 1. Clinical characteristics of 24 patients with CHARGE syndrome.
Patient Age1 Sex CHD7 Mutation Clinical CHARGE
syndrome2
Infectious history ENT
procedures
Atopy Cardiac surgery
UAI Pneumonia Other A/T tubes
CHD01 14.9 F 5222G>C mis typical + − − − − − −
CHD02 8.3 M 1480C>T non typical +4 − ++4 + + − −
CHD04 3.8 F 8077-1G>A splice atypical + − − − + − −
CHD05 13.8 M 2442+5G>C splice typical + − + − − − −
CHD06 16.9 M 2442+5G>C splice atypical + − + + − − −
CHD08 11.6 F 5405-17G>A splice atypical + − − − + − −
CHD09 3.2 M 5405-17G>A splice typical +4 − − − + all −
CHD10 2.3 F 5428C>T non typical − ++3 − − − − +
CHD11 13.5 M 8016G>A non typical +3 +3 − − + − −
CHD12 5.9 F 5944_5989dup fs typical + +3 − + − all −
CHD13 5.8 M 7160C>A non typical +3 − − − + − −
CHD14 6.6 M 5241-5244del fs atypical +3 − ++3 + + − +
CHD15 14.4 F 5833C>T non typical +5 − − + − all +
CHD16 15.5 M 7650_7651del fs atypical − ++4 − − − − −
CHD17 2.9 M 964delTT fs typical +5 − ++3 − − ecz −
CHD18 1.9 F 4542dup fs typical − ++4 ++3 − − − +
CHD19 14.9 M 5405-17G>A splice typical + − − + + all −
CHD20 8.4 M 3514_3515del fs typical + − ++3 − − − −
CHD21 14.9 F 5181C>G non typical +3 − − − + all; ecz −
CHD22 3.1 F Deletion 8q12.1q12.3 del typical ++3 − − + + − −
CHD23 8.1 M 4731delA fs typical +3 − − − − all −
CHD25 4.1 M 4783C>T non typical − ++4 − − − − −
CHD26 11.8 M 5051-15T>A splice typical + − − − + − +
CHD27 10.7 F 2572C>T non typical + ++3 +3 − + asthma +
-, none; +, yes; ++, yes, including hospital admission
1 Age in years at time of evaluation
2 Based on the criteria by Blake et al. [2] and/or Verloes [3]
3 Antibiotics given
4 Antibiotics given in addition to prophylactic antibiotics
5 Prophylatic antibiotics given
all, allergy; A/T, adenectomy and/or tonsillectomy; del, deletion; ecz, eczema; F, female; fs, frameshift; M, male; mis, missense; n, number; non,
nonsense; splice, splice site; tubes, tympanostomy tubes; UAI, upper airway infection, including otitis media
doi:10.1371/journal.pone.0142350.t001
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Humoral immunity
Humoral immunity was evaluated by determining immunoglobulin levels and absolute num-
bers of peripheral B-cells and B-cell subpopulations. The levels of immunoglobulins and
immunoglobulin subclasses are shown in Table 2 and were normal in all 24 patients, except for
one who had a marginally decreased IgA level of 0.50 g/l (normal 0.54 g/l).
Absolute numbers of peripheral B-cells and B-cell subpopulations, in which relevant results
were found, are shown in Table 3. Three (13%) patients had low numbers of B-cells. The abso-
lute number of memory B-cells, consisting mainly of class-switched memory B cells and a
small amount of IgM-only B-cells, is only slightly lower than the reference value in 4 of 24
(17%) CHARGE patients. Absolute numbers of all other peripheral B-cell subpopulations
(transitional, naive mature, marginal zone-like, plasmablasts and CD21low B-cells) were nor-
mal or only slightly decreased in all CHARGE patients (see S1 Table).
Interestingly, in eight patients (33%), the memory B-cells, which clearly had undergone
class-switch recombination as shown by strong IgG expression, retained IgM expression
(Table 3 and Fig 1).
Table 2. Immunoglobulin levels per CHARGE patient.
Patient Immunoglobulin levels1
IgG IgA IgM IgG1 IgG2 IgG3 IgG4 IgE
CHD01 9.8 (5.2–15.6) 1.3 (0.54–3.6) 1.6 (0.13–2.4) 7.4 (3.7–12.8) 2.0 (0.85–6.1) 0.6 (0.13–1.63) 0.5 (0.023–2.3) 13 (<100)
CHD02 8.2 (5.2–15.6) 1.1 (0.54–3.6) 0.6 (0.13–2.4) 6.3 (3.7–12.8) 1.5 (0.85–6.1) 0.3 (0.13–1.63) 0.2 (0.023–2.3) 29 (<50)
CHD04 9.2 (4.3–13.4) 1.2 (0.19–2.2) 1.3 (0.21–1.8) 7.3 (3.2–12.8) 1.5 (0.52–3.4) 0.4 (0.13–1.33) 0.2 (0.012–1.58) 20 (<10)
CHD05 6.1 (5.2–15.6) 0.5 (0.54–3.6) 0.9 (0.13–2.4) 5.4 (3.7–12.8) 1.3 (0.85–6.1) 0.3 (0.13–1.63) 0.2 (0.023–2.3) 84 (<100)
CHD06 8.0 (7.0–16.0) 0.7 (0.70–4.0) 0.9 (0.40–2.3) 5.9 (3.7–12.8)) 2.1 (0.85–6.1) 0.7 (0.13–1.63) 0.1 (0.023–2.3) 420 (<100)
CHD08 10.1 (5.2–15.6) 1.2 (0.54–3.6) 0.6 (0.13–2.4) 7.6 (3.7–12.8) 1.8 (0.85–6.1) 0.9 (0.13–1.63) 1.3 (0.023–2.3) 12 (<100)
CHD09 7.2 (4.3–13.4) 0.4 (0.19–2.2) 1.0 (0.21–1.8) 6.0 (3.2–10.0) 1.3 (0.52–3.4) 0.2 (0.13–1.33) 0.5 (0.012–1.58) <2.0 (<10)
CHD10 7.0 (4.3–13.4) 0.5 (0.19–2.2) 1.1 (0.21–1.8) 5.8 (3.2–10.0) 1.6 (0.52–3.4) 0.3(0.13–1.33) 0.8 (0.012–1.58) 15 (<10)
CHD11 9.9 (5.2–15.6) 2.5 (0.54–3.6) 0.7 (0.13–2.4) 5.9 (3.7–12.8) 3.5 (0.85–6.1) 0.3 (0.13–1.63) 0.5 (0.023–2.3) 13 (<100)
CHD12 9.7 (4.3–13.4) 1.2 (0.19–2.2) 1.1 (0.21–1.8) 5.6 (3.2–10.0) 3.0 (0.52–3.4) 0.4 (0.13–1.33) 2.2 (0.012–1.58) 145 (<50)
CHD13 6.8 (4.3–13.4) 0.6 (0.19–2.2) 0.7 (0.21–1.8) 6.0 (3.2–10.0) 0.8 (0.52–3.4) 0.3 (0.13–1.33) <0.1 (0.012–1.58) 24 (<25)
CHD14 7.0 (5.2–15.6) 1.2 (0.54–3.6) 1.3 (0.13–2.4) 5.4 (3.7–12.8) 2.1 (0.85–6.1) 0.3 (0.13–1.63) 0.3 (0.023–2.3) 7.5 (<25)
CHD15 12.3 (5.2–15.6) 2.1 (0.54–3.6) 1.2 (0.13–2.4) 8.1 (3.7–12.8) 3.4 (0.85–6.1) 0.4 (0.13–1.63) 3.0 (0.023–2.3) 70 (<100)
CHD16 9.4 (5.2–15.6) 1.1 (0.54–3.6) 0.5 (0.13–2.4) 7.0 (3.7–12.8) 1.8 (0.85–6.1) 0.3 (0.13–1.63) 0.8 (0.023–2.3) 22 (<100)
CHD17 11.2 (4.3–13.4) 0.8 (0.19–2.2) 1.0 (0.21–1.8) 9.2 (3.7–12.8) 1.2 (0.52–3.4) 0.4 (0.13–1.33) 0.3 (0.012–1.58) 70 (<10)
CHD18 8.3 (2.6–15.2) 0.7 (0.16–1.1) 0.9 (0.10–1.2) 7.3 (2.0–8.5) 1.3 (0.34–2.6) 0.5 (0.15–1.13) <0.1 (0.011–0.79) 2.9 (<10)
CHD19 12.8 (5.2–15.6) 0.9 (0.54–3.6) 1.5 (0.13–2.4) 8.0 (3.7–12.8) 3.1 (0.85–6.1) 0.7 (0.13–1.63) 0.2 (0.023–2.3) 7.1 (<100)
CHD20 11.0 (5.2–15.6) 1.1 (0.54–3.6) 1.5 (0.13–2.4) 9.2 (3.7–12.8) 1.4 (0.85–6.1) 0.5 (0.13–1.63) 0.5 (0.023–2.3) 27 (<50)
CHD21 11.4 (5.2–15.6) 3.1 (0.54–3.6) 1.8 (0.13–2.4) 8.3 (3.7–12.8) 3.0 (0.85–6.1) 0.5 (0.13–1.63) 2.0 (0.023–2.3) 1231 (<100)
CHD22 6.1 (4.3–13.4) 0.5 (0.19–2.2) 0.9 (0.21–1.8) 5.2 (3.2–10.0) 1.2 (0.52–3.4) 0.2 (0.13–1.33) <0.1 (0.012–1.58) 190 (<10)
CHD23 6.7 (5.2–15.6) 1.3 (0.54–3.6) 1.0 (0.13–2.4) 5.6 (3.7–12.8) 1.7 (0.85–6.1) 0.3 (0.13–1.63) <0.1 (0.023–2.3) 26 (<50)
CHD25 12.0 (4.3–13.4) 1.4 (0.19–2.2) 0.8 (0.21–1.8) 9.2 (3.2–10.0) 1.3 (0.52–3.4) 0.4 (0.13–1.33) 0.4 (0.012–1.58) 160 (<25)
CHD26 12.7 (5.2–15.6) 2.3 (0.54–3.6) 2.2 (0.13–2.4) 10.6 (3.7–12.8) 0.9 (0.85–6.1) 0.5 (0.13–1.63) 0.2 (0.023–2.3) 56 (<100)
CHD27 13.3 (5.2–15.6) 1.7 (0.54–3.6) 2.3 (0.13–2.3) 10.0 (3.7–12.8) 3.3 (0.85–6.1) 1.1 (0.13–1.63) 1.0 (0.023–2.3) 138 (<100)
1 Immunoglobulin concentration in g/l, except for IgE (IE/ml). Age-matched reference values are shown in brackets [12]. Values below or above the age-
matched reference values are shown in bold.
doi:10.1371/journal.pone.0142350.t002
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Thus, immunoglobulin production and peripheral B-cell differentiation were normal in our
CHARGE patients, except for the abnormal expression of IgM on class-switched memory B-
cells in a third of the patients.
Cellular immunity
Cellular immunity was evaluated by determining absolute numbers of peripheral NK-cells, T-
cells and T-cell subpopulations, TRECs, and T-cell function. In Table 4, the results of periph-
eral NK-cells, T-cells and naive T-cells are shown. Two of 24 (8%) patients had low numbers of
NK-cells. Overall, 12 of 24 (50%) patients had low peripheral T-cell numbers (CD3+, CD4
+ and/or CD8+ T-cells), of which five (21%) had low numbers of CD3+ T-cells, five (21%) had
low numbers of CD4+ T-cells, and eleven (46%) had low numbers of CD8+ T-cells. Compared
Table 3. Peripheral B-cells, memory B-cells and IgM expression on class-switchedmemory B-cells per CHARGE patient.
Patient B-cells1 Memory B-
cells1
Class-switched memory B-
cells2
IgM-only memory B-
cells2
IgM expression on class-switched memory B-
cells
CD45+ CD19+ CD27+ IgD- CD27+ IgD- IgM-/CD27
+IgD-IgG+
CD27+ IgD- IgG- IgM+ CD27+ IgD- IgM-/CD27+IgD-IgG+
CHD01 397 (200–500) 23 (10–76) 22 1 IgM expression3
CHD02 420 (300–700) 18 (13–100) 18 1 N
CHD04 696 (400–1500) 52 (20–149) 46 5 IgM expression3
CHD05 430 (200–500) 26 (10–76) 24 2 IgM expression3
CHD06 360 (100–400) 19 (12–122) 19 1 IgM expression3
CHD08 282 (200–500) 18 (10–76) 18 0 N
CHD09 656 (400–1500) 31 (20–149) 26 5 N
CHD10 1287 (400–
1500)
44 (20–149) 41 3 N
CHD11 488 (200–500) 38 (10–76) 37 1 IgM expression3
CHD12 562 (300–700) 76 (13–100) 74 2 N
CHD13 542 (300–700) 43 (13–100) 41 3 N
CHD14 409 (300–700) 15 (13–100) 14 1 N
CHD15 173 (200–500) 16 (10–76) 15 0 IgM expression3
CHD16 263 (200–500) 9 (10–76) 8 1 N
CHD17 534 (400–1500) 19 (20–149) 17 1 N
CHD18 748 (900–2500) 8 (9–114) 8 1 N
CHD19 273 (200–500) 15 (10–76) 14 1 IgM expression3
CHD20 350 (300–700) 45 (13–100) 36 9 N
CHD21 376 (200–500) 36 (10–76) 34 2 N
CHD22 1108 (400–
1500)
45 (20–149) 44 1 IgM expression3
CHD23 337 (300–700) 23 (13–100) 21 1 N
CHD25 509 (400–1500) 15 (20–149) 12 2 N
CHD26 179 (200–500) 14 (10–76) 12 2 N
CHD27 281 (200–500) 10 (10–76) 7 3 N
1 Absolute numbers in cells/μl. Age-matched reference values are shown in brackets [13,14]. Values below the age-matched reference values are shown
in bold.
2 No age-matched reference values available
3 Class-switched memory B-cells, as shown by strong IgG expression, also retaining IgM expression.
N, normal (no expression of IgM on class-switched memory B-cells).
doi:10.1371/journal.pone.0142350.t003
Immune Dysfunction in CHARGE Syndrome
PLOSONE | DOI:10.1371/journal.pone.0142350 November 6, 2015 7 / 16
to the healthy control group, decreased CD8+ T-cell numbers were found more often in
CHARGE patients (p = 0.031). Decreased numbers of CD4+ T-cells also occurred more often
in CHARGE patients than in the healthy control group, but this difference was not significant
(p = 0.146).
In the T-cell subpopulations, we primarily saw deviations in the number of naive mature T-
cells. The absolute or relative numbers of other T-cell subpopulations (central memory, effector
memory, terminally differentiated, activated, CD4+ regulatory, αβ, γδ and double negative αβ
T-cells) were not abnormal in a relevant way (S2 Table). For seven patients, T-cell subpopula-
tions could not be interpreted because age-matched reference values were not available. Of the
other seventeen patients, five (29%) and eight (47%) patients had low numbers of naive mature
CD4+ T-cells and naive mature CD8+ T-cells, respectively. Most patients with low numbers of
naive mature CD4+ or CD8+ T-cells also had low numbers of total CD4+ T or CD8+ T-cells.
Fig 1. IgM and IgG expression onmemory B-cells. IgM and IgG expression on memory B-cells (CD27
+IgD-) of a CHARGE patient (B, D) and a simultaneously analyzed healthy control (A, C). A, B) IgG and IgM
expression are used to differentiate between class-switched memory B-cells (CD27+IgD-IgM-/CD27
+IgD-IgG+) and IgM-only memory B-cells (CD27+IgD-IgG-IgM++). Memory B-cells with high IgM expression
and no expression of IgG are considered to be IgM-only memory B-cells (upper-left quadrant), all other
memory B-cells are considered to be class-switched memory B-cells. C, D) Part of the CHARGE patients
show abnormal expression of IgM on class-switched memory B-cells compared to healthy controls. MFI,
mean fluorescence intensity.
doi:10.1371/journal.pone.0142350.g001
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Table 4. Peripheral NK-cells, T-cells and naive T-cells per CHARGE patient.
Patient NK-cells1 CD3+ T-
cells1
CD4+ T-
cells1
Naive mature CD4
+ T-cells2
Naive mature CD4
+ T-cells2
CD8+ T-
cells1
Naive mature CD8
+ T-cells2
Naive mature CD8
+ T-cells2
CD16+56+ CD45+ CD3
+
CD3+ CD4+ CD45R0- CCR7
+ CD27+ CD28+
CD45R0- CCR7
+ CD27+ CD28+
CD3+ CD8
+
CD45R0- CCR7
+ CD27+ CD28+
CD45R0- CCR7
+ CD27+ CD28+
CHD01 261 (100–
700)
1628 (1000–
2000)
884 (500–
1300)
527 (277–796) 59.6% (42.4–66.3) 578 (300–
800)
396 (205–465) 68.5% (48.8–72.9)
CHD02 584 (100–
600)
1755 (1100–
2800)
1209 (500–
1800)
800 (515–913) 66.2% (60.2–74.6) 446 (400–
1200)
261 (369–578) 58.6% (49.1–78.8)
CHD04 117 (100–
700)
2010 (1400–
3600)
1322 (700–
2000)
1000 (n/a) 75.7% (n/a) 500 (500–
1400)
405 (n/a) 81.1% (n/a)
CHD05 88 (100–
700)
1641 (1000–
2000)
1001 (500–
1300)
629 (277–796) 62.8% (42.4–66.3) 452 (300–
800)
273 (205–465) 60.3% (48.8–72.9)
CHD06 110 (100–
400)
1110 (700–
1900)
610 (400–
1300)
338 (277–796) 55.4% (42.4–66.3) 250 (200–
700)
147 (205–465) 58.6% (48.8–72.9)
CHD08 230 (100–
700)
1285 (1000–
2000)
732 (500–
1300)
394 (277–796) 53.8% (42.4–66.3) 392 (300–
800)
229 (205–465) 58.4% (48.8–72.9)
CHD09 467 (100–
700)
1458 (1400–
3600)
862 (700–
2000)
553 (n/a) 64.2% (n/a) 417 (500–
1400)
325 (n/a) 77.9% (n/a)
CHD10 957 (100–
700)
2546 (1400–
3600)
1488 (700–
2000)
1019 (n/a) 68.5% (n/a) 813 (500–
1400)
236 (n/a) 29.1% (n/a)
CHD11 234 (100–
700)
1282 (1000–
2000)
845 (500–
1300)
488 (277–796) 57.8% (42.4–66.3) 340 (300–
800)
198 (205–465) 58.4% (48.8–72.9)
CHD12 182 (100–
600)
1374 (1100–
2800)
915 (500–
1800)
390 (515–913) 42.7% (60.2–74.6) 357 (400–
1200)
115 (369–578) 32.2% (49.1–78.8)
CHD13 372 (100–
600)
2192 (1100–
2800)
1269 (500–
1800)
814 (515–913) 64.2% (60.2–74.6) 652 (400–
1200)
247 (369–578) 37.9% (49.1–78.8)
CHD14 330 (100–
600)
899 (1100–
2800)
458 (500–
1800)
215 (515–913) 47.0% (60.2–74.6) 297 (400–
1200)
87 (369–578) 29.3% (49.1–78.8)
CHD15 172 (100–
700)
1110 (1000–
2000)
787 (500–
1300)
490 (277–796) 62.3% (42.4–66.3) 250 (300–
800)
138 (205–465) 55.5% (48.8–72.9)
CHD16 184 (100–
700)
1042 (1000–
2000)
308 (500–
1300)
111 (277–796) 36.2% (42.4–66.3) 649 (300–
800)
115 (205–465) 17.7% (48.8–72.9)
CHD17 118 (100–
700)
1622 (1400–
3600)
894 (700–
2000)
691 (n/a) 77.3% (n/a) 520 (500–
1400)
79 (n/a) 71.8% (n/a)
CHD18 219 (100–
1100)
1483 (2200–
5500)
1008 (1100–
3600)
725 (n/a) 72.0% (n/a) 373 (500–
1800)
310 (n/a) 83.2% (n/a)
CHD19 303 (100–
700)
887 (1000–
2000)
507 (500–
1300)
250 (277–796) 49.3% (42.4–66.3) 230 (300–
800)
94 (205–465) 41.0% (48.8–72.9)
CHD20 580 (100–
600)
940 (1100–
2800)
400 (500–
1800)
138 (515–913) 34.5% (60.2–74.6) 290 (400–
1200)
73 (369–578) 25.1% (49.1–78.8)
CHD21 187 (100–
700)
1455 (1000–
2000)
917 (500–
1300)
654 (277–796) 71.4% (42.4–66.3) 417 (300–
800)
310 (205–465) 74.6% (48.8–72.9)
CHD22 354 (100–
700)
1431 (1400–
3600)
1035 (700–
2000)
602 (n/a) 58.1% (n/a) 182 (500–
1400)
102 (n/a) 56.2% (n/a)
CHD23 192 (100–
600)
1239 (1100–
2800)
734 (500–
1800)
495 (515–913) 67.5% (60.2–74.6) 365 (400–
1200)
265 (369–578) 72.8% (49.1–78.8)
CHD25 98 (100–
700)
1404 (1400–
3600)
896 (700–
2000)
625 (n/a) 69.7% (n/a) 422 (500–
1400)
315 (n/a) 74.7% (n/a)
CHD26 656 (100–
700)
1261 (1000–
2000)
775 (500–
1300)
511 (277–796) 65.9% (42.4–66.3) 342 (300–
800)
143 (205–465) 41.9% (48.8–72.9)
(Continued)
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Decreased numbers of naive mature CD4+ T-cells (p = 0.059) and naive mature CD8+ T-cells
(p = 0.009) occurred more often in CHARGE patients than in the healthy control group.
Low numbers of naive mature and total T-cells can be caused by congenital thymic aplasia
or hypoplasia, both of which have been described in patients with CHARGE syndrome [9].
However, low numbers of naive mature and total T-cells may also be caused by thymectomy
during cardiac surgery due to congenital heart defects in CHARGE patients. Information on
the thymus was available for six patients who had undergone cardiac surgery (Table 1). Two
patients (CHD18 and 27) had thymectomy during cardiac surgery and had low peripheral T-
cells. One patient (CHD 26) had only a partial thymectomy and had normal T-cell numbers
(except for low naive CD8+ T-cells). In one patient (CHD14) thymus aplasia was confirmed
during surgery, with resulting low T-cell numbers. The thymus was not mentioned in the oper-
ation reports for the other two patients (CHD10 and 15). Of the eighteen patients without car-
diac surgery, eight patients (CHD09, 12, 16, 19, 20, 22, 23 and 25; 44%) had low peripheral T-
cell numbers (CD3+, CD4+ and/or CD8+ T-cells).
TREC analysis could be performed in 22 patients with CHARGE syndrome. The mean
TRECs/μg DNA was 998 (SD 535), which is significantly lower than the TRECs in the healthy
control group (Fig 2, mean 1688, SD 814, p = 0.005). To evaluate the effect of age on the
amount of TRECs, a linear regression analyses was performed and showed no significant effect.
Overall, the results of all 24 patients showed sufficient T-cell activation and intracellular
cytokine production after stimulation with different mitogenic and antigenic stimuli (S3
Table). Of note, 11 (46%) patients had increased T-cell responses to one or more stimuli, com-
pared to the age-matched reference values established on the results of our 12 healthy controls.
Eight of these patients had decreased percentages of naive mature T-cells and increased per-
centages of effector memory or terminally differentiated T-cells, which might be an explana-
tion of the increased responses.
In summary, 50% of patients had low peripheral T-cell numbers, mainly caused by low
numbers of naive mature T-cells, which is consistent with the decreased numbers of TRECs.
Although the numbers of T-cells are decreased, deficiencies in T-cell function were not found
with the assay we performed.
Vaccination responses
All patients were vaccinated according to the Dutch or Belgian National Immunization Pro-
grammes [24,25], with the exception of one patient who had not been vaccinated at all
(Table 5). Levels of IgG-specific antibodies to tetanus toxin were normal in all vaccinated
patients. Eight of 22 (36%; assessment was unsuccessful in one patient) vaccinated patients had
Table 4. (Continued)
Patient NK-cells1 CD3+ T-
cells1
CD4+ T-
cells1
Naive mature CD4
+ T-cells2
Naive mature CD4
+ T-cells2
CD8+ T-
cells1
Naive mature CD8
+ T-cells2
Naive mature CD8
+ T-cells2
CHD27 452 (100–
700)
606 (1000–
2000)
368 (500–
1300)
109 (277–796) 29.5% (42.4–66.3) 169 (300–
800)
7 (205–465) 4.1% (48.8–72.9)
1 Absolute numbers in cells/μl. Age-matched reference values are shown in brackets [13,15]. Values below the age-matched reference values are shown
in bold.
2 Absolute numbers in cells/μl and relative numbers in percentages of naive mature CD4+ or CD8+ T-cells. Age-matched reference values are shown in
brackets [15]. If both the absolute and the relative numbers are below the age-matched reference values, values are shown in bold.
n/a, age-matched reference value not available
doi:10.1371/journal.pone.0142350.t004
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insufficient levels of IgG-specific antibodies to diphtheria and 15 of 23 (65%) vaccinated
patients had insufficient levels of IgG-specific antibodies toH. influenzae type b. The vaccina-
tion response to pneumococcal polysaccharides could only be interpreted in 11 patients, since
vaccination to pneumococcal polysaccharides was introduced into the Dutch vaccination pro-
gramme in 2006. Three of 11 (27%) patients had insufficient antibodies to pneumococcal poly-
saccharides. Of 23 vaccinated patients, 19 (83%) had insufficient levels of IgG-specific
antibodies to one or more of the vaccines we tested, while only four patients had sufficient lev-
els of IgG-specific antibodies to all of the vaccines tested. Overall, reduced responses to one or
more vaccinations, given in early childhood, are prevalent in patients with CHARGE
syndrome.
Discussion
This is the first study to systematically and extensively explore the immune system of
CHARGE patients. In our cohort of CHARGE patients, all had a history of infections (often
frequent), specifically upper airway infections that often led to hospital admissions and the use
of prophylactic antibiotics. Anomalies in the upper airway (atresia of choanae, abnormal outer
and inner ear anatomy) contribute to patient susceptibility to infections and extend infection
duration by impeding drainage or clearance of infectious debris. It is, however important, to
know whether immunological abnormalities contribute to the frequency and complicate the
severity of infections in order to optimize the management of care in these patients.
No abnormalities were found in routine diagnostics (full blood count), but with detailed
immunologic assays, we found T-cell lymphopenia in 50% of patients, mainly caused by low
numbers of naive mature T-cells. Our finding is comparable with the results of a retrospective
study by Jyonouchi et al. [8], who found overall T-cell lymphopenia in four of nine (44%)
CHARGE patients.
Notably, we found low T-cell numbers in 44% of patients who had not undergone cardiac
surgery and therefore should have an “intact” thymus. Congenital dysmorphology or dysfunc-
tion of the thymus might be the underlying cause of T-cell lymphopenia and this is supported
Fig 2. T-cell receptor excision circle (TREC) analysis.Numbers of TRECs in patients with CHARGE
syndrome (n = 22) compared to healthy controls (n = 12). Error bars indicate means and standard deviations,
*p = 0.005.
doi:10.1371/journal.pone.0142350.g002
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by our finding of diminished TREC numbers in the patients. Little is known about thymic
abnormalities in CHARGE patients from the literature. Thymic anomalies have been reported
in foetuses with confirmed CHD7mutations [26] and were reported in 16 of 36 (44%) patients
with a proven mutation in CHD7 [9]. Unfortunately, there is no specific information on the
thymus for 18 of 24 patients in our CHARGE cohort.
Evidence for the role of CHD7 and TBX1, the causative gene of 22q11.2 deletion syndrome,
has been shown in the embryonic development of the thymus in animal models. Both genes
are expressed in the pharyngeal arches which contain precursors of thymic stromal cells
[27,28]. Bi-directional molecular interaction between thymic epthelial cells and T-cell progeni-
tor cells is critical for the complete morphological and functional maturation of both cell com-
partments [27]. Thus, abnormal thymic development presumably not only affects the level of
T-cell output, but could also affect the function of T-cells. For example, the T-cell receptor rep-
ertoire [29] and the development of natural regulatory T-cells [30] have been shown to be
affected in patients with 22q11.2 deletion syndrome. Although we found normal T-cell
responses with our T-cell function assay, we cannot exclude subtle dysfunctions in more com-
plex T-cell function, such as the delicate interaction between T-cells and B-cells.
Peripheral B-cell and NK-cell numbers were normal in almost all patients, comparable to
former reports [9]. However, hypogammaglobulinaemia was found in 61% of CHARGE
patients in former case reports [9], while in our study the immunoglobulin levels were normal
in all patients. Publication bias needs to be taken in consideration for the higher percentages
found in case reports. Actually, our results were more comparable with those from 22q11.2
deletion syndrome, where hypogammaglobulinaemia was found in only 6% of a large cohort of
855 patients [31]. Although peripheral B-cell differentiation was normal, a third of the
CHARGE patients had class-switched memory B-cell retaining IgM expression. We had not
anticipated on this finding in our methods by including isotype controls, which limits the inter-
pretation of these data. Nonetheless, these cells may indicate impaired class-switch recombina-
tion and memory B-cell formation in CHARGE patients. To our knowledge, these
phenotypically abnormal class-switched memory B-cells have not been reported before, but
lower numbers of class-switched memory B-cells have been found in adults with 22q11.2 dele-
tion syndrome [32]. We can speculate that the formation of fully functional class-switched
memory B-cells in CHARGE patients is impeded due to insufficient T-cell help during the
class-switch recombination process, leading to diminished production of specific antibodies.
However, our data is insufficient to fully support this tentative hypothesis which links our find-
ings in the peripheral T-cell populations with the humoral abnormalities. More research is
needed on memory B-cell formation and function in CHARGE patients.
Specific antibodies to one or more vaccines given in childhood were insufficient in 83% of
patients, specifically to diphtheria andH. influenzae type b vaccines. In the literature, vaccina-
tion responses in CHARGE syndrome are only described in case reports and in one retrospec-
tive study. Reduced responses to diphtheria (n = 3), tetanus (n = 4), H. influenzae type b
(n = 2), and pneumococcal polysaccharides (n = 1) have been reported [8,33,34]. Although
protective levels of specific antibodies decrease over time, this waning seems to occur at an ear-
lier age in patients with CHARGE syndrome (median age 14.7 years) compared with the gen-
eral population (30–40 years of age) [35,36].
We studied the largest cohort of well-defined CHARGE patients with confirmed CHD7
mutations so far but, of course, statistical analysis on only 24 patients limits the interpretation
of our results. What we can state is that immunological abnormalities are often seen in patients
with CHARGE syndrome. We hypothesize that abnormal thymic development leads to dimin-
ished numbers of T-cells that may also be impaired in more subtle functions as activating B-
cells to differentiate into fully functional class-switched memory B-cells. Incomplete class-
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switched memory B-cell formation can be an explanation for the insufficient responses to vac-
cines in our CHARGE patients due to poor humoral memory.
The high prevalence of immunological abnormalities combined with the frequent occur-
rence of infections demonstrates the need for more research in a larger cohort to extend the
analysis of correlations between clinical data and immunological laboratory results, and to con-
firm some of our immunological findings. With such data, evidence-based guidelines can be
developed for the timely diagnosis of immune dysfunctions based on clinical symptoms, which
will help protect these children from excess morbidity and mortality due to infections. None-
theless, based on the results of this study, we would recommend performing specialised immu-
nologic assays (B- and T-cell numbers and vaccination responses) in patients with persistent
infections who need prophylactic antibiotics, since the immune abnormalities we found will
not be apparent with routine diagnostics. Considering the high prevalence of reduced antibody
responses, it may be worthwhile to give these patients booster vaccinations and recheck the
antibody responses. Firstly becauseH. influenza and pneumococcal infections are highly preva-
lent in otitis media [37], and secondly to determine if CHARGE patients have a primary lack of
response to some vaccines or if they have poor humoral memory.
Supporting Information
S1 Appendix. Monoclonal antibodies and gating strategy for the B- and T-cell subpopula-
tions.
(DOC)
S2 Appendix. Stimulation, fluorescent barcoding, and monoclonal antibodies in the T-cell
function assay.
(DOCX)
S1 Dataset. Data of the T-cell receptor excision circle analysis.
(XLSX)
S1 Table. Peripheral B-cell subpopulations per CHARGE patient.
(DOC)
S2 Table. Peripheral T-cells subpopulations per CHARGE patient.
(DOC)
S3 Table. T-cell function assay per CHARGE patient.
(XLS)
Acknowledgments
Foremost, we would like to thank the patients, their siblings, and their parents for their cooper-
ation in the study. We thank Eelco Dulfer for recruiting eligible participants; Jetske T. Anema,
Janneke Heimweg, Bessel J. Schaap, and Ingrid Pico-Knijnenburg for analyzing the samples
and Kate Mc Intyre for editing the manuscript.
Author Contributions
Conceived and designed the experiments: MTYW AJAL CMAR-A EHS. Performed the experi-
ments: MTYW AJAL MB LAH EHS. Analyzed the data: MTYW AJAL MB SB-G EHS. Con-
tributed reagents/materials/analysis tools: MTYW AJAL MB LAH EHS. Wrote the paper:
MTYW AJAL MB SB-G CMAR-A EHS.
Immune Dysfunction in CHARGE Syndrome
PLOSONE | DOI:10.1371/journal.pone.0142350 November 6, 2015 14 / 16
References
1. Janssen N, Bergman JE, Swertz MA, Tranebjaerg L, Lodahl M, Schoots J, et al. Mutation update on the
CHD7 gene involved in CHARGE syndrome. HumMutat. 2012; 33: 1149–1160. doi: 10.1002/humu.
22086 PMID: 22461308
2. Blake KD, Davenport SL, Hall BD, Hefner MA, Pagon RA, Williams MS, et al. CHARGE association: an
update and review for the primary pediatrician. Clin Pediatr (Phila). 1998; 37: 159–173.
3. Verloes A. Updated diagnostic criteria for CHARGE syndrome: a proposal. Am J Med Genet A. 2005;
133: 306–308.
4. Bergman JE, Janssen N, van der Sloot AM, de Walle HE, Schoots J, Rendtorff ND, et al. A novel classi-
fication system to predict the pathogenic effects of CHD7missense variants in CHARGE syndrome.
HumMutat. 2012; 33: 1251–1260. doi: 10.1002/humu.22106 PMID: 22539353
5. Pagon RA, Graham JM Jr., Zonana J, Yong SL. Coloboma, congenital heart disease, and choanal atre-
sia with multiple anomalies: CHARGE association. J Pediatr. 1981; 99: 223–227. PMID: 6166737
6. Jongmans MC, Admiraal RJ, van der Donk KP, Vissers LE, Baas AF, Kapusta L, et al. CHARGE syn-
drome: the phenotypic spectrum of mutations in the CHD7 gene. J Med Genet. 2006; 43: 306–314.
PMID: 16155193
7. Bergman JE, Janssen N, Hoefsloot LH, Jongmans MC, Hofstra RM, van Ravenswaaij-Arts CM. CHD7
mutations and CHARGE syndrome: the clinical implications of an expanding phenotype. J Med Genet.
2011; 48: 334–342. doi: 10.1136/jmg.2010.087106 PMID: 21378379
8. Jyonouchi S, McDonald-Mcginn DM, Bale S, Zackai EH, Sullivan KE. CHARGE (coloboma, heart
defect, atresia choanae, retarded growth and development, genital hypoplasia, ear anomalies/deaf-
ness) syndrome and chromosome 22q11.2 deletion syndrome: a comparison of immunologic and non-
immunologic phenotypic features. Pediatrics. 2009; 123: e871–e877. doi: 10.1542/peds.2008-3400
PMID: 19403480
9. WongMT, Scholvinck EH, Lambeck AJ, van Ravenswaaij-Arts CM. CHARGE syndrome: a review of
the immunological aspects. Eur J HumGenet. 2015.
10. de Vries E, Clinical Working Party of the European Society for Immunodeficiencies (ESID). Patient-cen-
tred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immu-
nologists. Clin Exp Immunol. 2006; 145: 204–214. PMID: 16879238
11. de Vries E, European Society for Immunodeficiencies (ESID) members. Patient-centred screening for
primary immunodeficiency, a multi-stage diagnostic protocol designed for non-immunologists: 2011
update. Clin Exp Immunol. 2012; 167: 108–119. doi: 10.1111/j.1365-2249.2011.04461.x PMID:
22132890
12. Jolliff CR, Cost KM, Stivrins PC, Grossman PP, Nolte CR, Franco SM, et al. Reference intervals for
serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. Clin Chem. 1982; 28: 126–128.
PMID: 7055895
13. Comans-Bitter WM, de Groot R, van den Beemd R, Neijens HJ, HopWC, Groeneveld K, et al. Immuno-
phenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J
Pediatr. 1997; 130: 388–393. PMID: 9063413
14. Driessen GJ, van ZelmMC, van Hagen PM, Hartwig NG, Trip M, Warris A, et al. B-cell replication his-
tory and somatic hypermutation status identify distinct pathophysiologic backgrounds in common vari-
able immunodeficiency. Blood. 2011; 118: 6814–6823. doi: 10.1182/blood-2011-06-361881 PMID:
22042693
15. Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M. Accumulation of memory T cells from
childhood to old age: central and effector memory cells in CD4(+) versus effector memory and termi-
nally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev. 2006; 127: 274–281.
PMID: 16352331
16. Stam J, AbdulahadW, Huitema MG, Roozendaal C, Limburg PC, van Stuijvenberg M, et al. Fluores-
cent cell barcoding as a tool to assess the age-related development of intracellular cytokine production
in small amounts of blood from infants. PLoS One. 2011; 6: e25690. doi: 10.1371/journal.pone.
0025690 PMID: 22043291
17. van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA. Development and validation of a
multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis,
diphtheria and tetanus. J Immunol Methods. 2008; 335: 79–89. doi: 10.1016/j.jim.2008.02.018 PMID:
18407287
18. van Gageldonk PG, von Hunolstein C, van der Klis FR, Berbers GA. Improved specificity of a multiplex
immunoassay for quantitation of anti-diphtheria toxin antibodies with the use of diphtheria toxoid. Clin
Vaccine Immunol. 2011; 18: 1183–1186. doi: 10.1128/CVI.05081-11 PMID: 21613460
Immune Dysfunction in CHARGE Syndrome
PLOSONE | DOI:10.1371/journal.pone.0142350 November 6, 2015 15 / 16
19. Elberse KE, Tcherniaeva I, Berbers GA, Schouls LM. Optimization and application of a multiplex bead-
based assay to quantify serotype-specific IgG against Streptococcus pneumoniae polysaccharides:
response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine.
Clin Vaccine Immunol. 2010; 17: 674–682. doi: 10.1128/CVI.00408-09 PMID: 20130129
20. Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, Elberse KE, van Gageldonk PG, Knol MJ, et al.
Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different
primary immunization schedules in infants: a randomized clinical trial. JAMA. 2013; 310: 930–937. doi:
10.1001/jama.2013.228052 PMID: 24002279
21. van ZelmMC, van der Burg M, Langerak AW, van Dongen JJ. PID comes full circle: applications of V
(D)J recombination excision circles in research, diagnostics and newborn screening of primary immu-
nodeficiency disorders. Front Immunol. 2011; 2: 12. doi: 10.3389/fimmu.2011.00012 PMID: 22566803
22. Hazenberg MD, Verschuren MC, Hamann D, Miedema F, van Dongen JJ. T cell receptor excision cir-
cles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for
interpretation. J Mol Med (Berl). 2001; 79: 631–640.
23. Chan K, Puck JM. Development of population-based newborn screening for severe combined immuno-
deficiency. J Allergy Clin Immunol. 2005; 115: 391–398. PMID: 15696101
24. [Anonymous]. National Immunisation Programme—National Institute for Public Health and the Environ-
ment. Available: http://www.rivm.nl/en/Topics/N/National_Immunisation_Programme.
25. [Anonymous]. Vaccination | Agentschap Zorg en Gezondheid. Available: http://www.zorg-en-
gezondheid.be/Diseases/Vaccination/.
26. Sanlaville D, Etchevers HC, Gonzales M, Martinovic J, Clement-Ziza M, Delezoide AL, et al. Pheno-
typic spectrum of CHARGE syndrome in fetuses with CHD7 truncating mutations correlates with
expression during human development. J Med Genet. 2006; 43: 211–217. PMID: 16169932
27. Hollander G, Gill J, Zuklys S, Iwanami N, Liu C, Takahama Y. Cellular and molecular events during
early thymus development. Immunol Rev. 2006; 209: 28–46. PMID: 16448532
28. Randall V, McCue K, Roberts C, Kyriakopoulou V, Beddow S, Barrett AN, et al. Great vessel develop-
ment requires biallelic expression of Chd7 and Tbx1 in pharyngeal ectoderm in mice. J Clin Invest.
2009; 119: 3301–3310. doi: 10.1172/JCI37561 PMID: 19855134
29. McLean-Tooke A, Barge D, Spickett GP, Gennery AR. Flow cytometric analysis of TCR Vbeta reper-
toire in patients with 22q11.2 deletion syndrome. Scand J Immunol. 2011; 73: 577–585. doi: 10.1111/j.
1365-3083.2011.02527.x PMID: 21323691
30. Poliani PL, Facchetti F, Ravanini M, Gennery AR, Villa A, Roifman CM, et al. Early defects in human T-
cell development severely affect distribution and maturation of thymic stromal cells: possible implica-
tions for the pathophysiology of Omenn syndrome. Blood. 2009; 114: 105–108. doi: 10.1182/blood-
2009-03-211029 PMID: 19414857
31. Patel K, Akhter J, Kobrynski L, Benjamin Gathmann MA, Davis O, Sullivan KE, et al. Immunoglobulin
deficiencies: the B-lymphocyte side of DiGeorge Syndrome. J Pediatr. 2012; 161: 950–953. doi: 10.
1016/j.jpeds.2012.06.018 PMID: 22809661
32. Zemble R, Luning Prak E, McDonald K, McDonald-McGinn D, Zackai E, Sullivan K. Secondary immu-
nologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofa-
cial syndrome). Clin Immunol. 2010; 136: 409–418. doi: 10.1016/j.clim.2010.04.011 PMID: 20472505
33. Chopra C, Baretto R, Duddridge M, Browning MJ. T-Cell Immunodeficiency in CHARGE syndrome.
Acta Paediatr. 2009; 98: 408–412. doi: 10.1111/j.1651-2227.2008.01077.x PMID: 18976358
34. Theodoropoulos DS. Immune deficiency in CHARGE association. Clin Med Res. 2003; 1: 43–48.
PMID: 15931284
35. de Melker HE, Berbers GA, Nagelkerke NJ, Conyn-van Spaendonck MA. Diphtheria antitoxin levels in
the Netherlands: a population-based study. Emerg Infect Dis. 1999; 5: 694–700. PMID: 10511526
36. de Melker HE, van den Hof S, Berbers GA, Conyn-van Spaendonck MA. Evaluation of the national
immunisation programme in the Netherlands: immunity to diphtheria, tetanus, poliomyelitis, measles,
mumps, rubella and Haemophilus influenzae type b. Vaccine. 2003; 21: 716–720. PMID: 12531347
37. van Dongen TM, Venekamp RP, Wensing AM, Bogaert D, Sanders EA, Schilder AG. Acute otorrhea in
children with tympanostomy tubes: prevalence of bacteria and viruses in the post-pneumococcal conju-
gate vaccine era. Pediatr Infect Dis J. 2015; 34: 355–360. doi: 10.1097/INF.0000000000000595 PMID:
25764097
Immune Dysfunction in CHARGE Syndrome
PLOSONE | DOI:10.1371/journal.pone.0142350 November 6, 2015 16 / 16
